What is Matinas BioPharma's market cap?

Matinas BioPharma (MTNB) has a market capitalization of $2.1M and trades on AMEX.

Who are Matinas BioPharma's competitors?

Matinas BioPharma's key competitors include Pfizer, Inc., Merck & Co., CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Matinas BioPharma partner with?

Matinas BioPharma's notable partners include Rutgers University, National Institute of Allergy and Infectious Diseases, Astellas Pharma US, Inc..

What subsidiaries does Matinas BioPharma have?

Matinas BioPharma's subsidiaries include Matinas BioPharma, Inc., Matinas BioPharma Nanotechnologies, Inc..

Where is Matinas BioPharma headquartered?

Matinas BioPharma is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2014.

Matinas BioPharma

MTNB

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in the delivery of high-potency therapies through its proprietary lipid nanocrystal (LNC) platform.

Market cap

$2.13M-50.2%

Table of contents

Earnings

Q1 2026 report

May 8, 2026

EPS-$0.30Beat by $1.02

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$25.0K

EPS estimate-$1.50

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

Lantheus Holdings$7.0B+40.4%

Clene Inc.$69.8M+128%

Lantern Pharma$35.6M-17.7%

NXT

NextCure, Inc.$20.8M+40.5%

CNS Pharmaceuticals$7.4M-83.4%

Matinas BioPharma$2.1M-55.0%

By revenue growth

Merck & Co.+2.9%

Pfizer+1.4%

Lantheus Holdings+0.6%

By net margin

Lantheus Holdings18.05%+0.7pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in the delivery of high-potency therapies through its proprietary lipid nanocrystal (LNC) platform. The company's core value proposition lies in its ability to reformulate toxic or poorly absorbed drugs into safer, oral delivery formats that facilitate targeted cellular delivery. Currently, the company is focused on securing strategic partnerships to advance its lead antifungal candidate into Phase 3 registration trials while evaluating broader strategic alternatives.

Competitive position

Matinas is a clinical-stage developer with a specialized drug delivery platform, currently seeking external partners to fund and execute late-stage clinical trials.

GeographiesUnited States, Europe, Global

Customer segmentsPharmaceutical companies, Healthcare providers

Business modelIP Licensing, Research and Development

SuppliersRutgers University (IP Licensing), Third-party API suppliers (Amphotericin B), Contract Research Organizations (CROs), National Institutes of Health (NIH/NIAID funding)

CustomersStrategic licensing partners, Specialty pharmaceutical companies, Healthcare institutions (Compassionate Use Program)

CountryUnited States of America

Listed2014

Employees34.0

CEOJerome D. Jabbour

SectorHealthcare

IndustryBiotechnology

Websitematinasbiopharma.com

FilingsSEC EDGAR

Questions, answered.

What is Matinas BioPharma's market cap?: Matinas BioPharma (MTNB) has a market capitalization of $2.1M and trades on AMEX.
Who are Matinas BioPharma's competitors?: Matinas BioPharma's key competitors include Pfizer, Inc., Merck & Co., CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Matinas BioPharma partner with?: Matinas BioPharma's notable partners include Rutgers University, National Institute of Allergy and Infectious Diseases, Astellas Pharma US, Inc..
What subsidiaries does Matinas BioPharma have?: Matinas BioPharma's subsidiaries include Matinas BioPharma, Inc., Matinas BioPharma Nanotechnologies, Inc..
Where is Matinas BioPharma headquartered?: Matinas BioPharma is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2014.